Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers May 27, 2017
Pharmacy Choice - News - Pharmaceutical Development - May 27, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/20/17 - Daewoong Seeks FDA Approval for Botulinum Toxin
Daewoong Pharmaceutical's botulinum toxin Nabota is expected to hit the US market by the end of 2018, fueling competition among rivals amid a near monopoly of Allergan.
5/20/17 - New Lenox hospital offers new implant for foot surgery
Anne McCall is always on her feet. As the medical director for radiation oncology at the University of Chicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, it's no surprise she walks all day. The new implant, called the Cartiva Synthetic Cartilage Implant, received FDA approval about a year ago.
5/19/17 - "Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use" in Patent Application Approval Process (USPTO 20170112821)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor Horn, Gerald, filed on January 9, 2017, was made available online on May 4, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company or institution. Due to the incr
5/19/17 - "Therapeutic Combinations of Sesquiterpenes and Flavonoids" in Patent Application Approval Process (USPTO 20170112802)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor Yamaguchi, Masayoshi, filed on October 14, 2016, was made available online on May 4, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Primus Pharmaceuticals, Inc.. Baicalin and
5/19/17 - Abeona Therapeutics to Present at Multiple Upcoming Conferences
ABO-102 gene therapy program for Sanfilippo syndrome Type A: Abeona announced top-line data for Phase 1/ 2 MPS IIIA gene therapy trial at ASGCT Positive dose response in central nervous system with 60.7%+/- 8.8% reduction of disease-causing heparan sulfate GAG observed in Cohort 2 Reduction of disease manifestation observed in decreased liver v
5/19/17 - ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Files An 8-K Results of Operations and Financial Condition
ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Files An 8-K Results of Operations and Financial Condition Item 2.02 Results of Operations and Financial Condition On May 18, 2017 we issued a press release announcing the announced that we completed enrollment and initiated dosing in a second Phase 1 human pharmacokinetic trial of LTX-04, our lead developm
5/19/17 - Aeterna Zentaris to Announce First Quarter 2017 Financial and Operating Results on May 8, 2017
By a News Reporter-Staff News Editor at Drug Week Aeterna Zentaris Inc. will announce its first quarter 2017 financial and operating results after market close on Monday, May 8, 2017. The Company will host a conference call and webcast to discuss these results on Tuesday, May 9, 2017 at 8:30 a.m. Eastern Time. About Aeterna Zentaris Inc. Aeterna
5/19/17 - Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHA [T-break Tech (Middle East)]
-Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic diseases, today announced that updated clinical data from the fully enrolled, ongoing Phase 2 study of AG-348 in adults with pyruvate kinase deficiency, a rare, potentially debilitating, congenital anemia, will be presented at the 22nd Congress of the Europea
5/19/17 - Albireo Unveils Plans for Phase 3 Clinical Program [Tehran Times (Iran)]
Albireo Pharma, Inc. was out Thursday with key study design details for a planned phase 3 program of lead product candidate, A4250, in patients with progressive familial intrahepatic cholestasis determined following consultations with the U.S. Food and Drug Administration and European Medicines Agency. PFIC is a rare and life-threatening genetic li
5/19/17 - Amicus Therapeutics Announces Planned Analysis of Primary Endpoints in Phase 3 Epidermolysis Bullosa Study
Amicus Therapeutics, Inc., has completed the analysis plan for the primary endpoints in the blinded ongoing Phase 3 clinical study of the novel topical medicine SD-101 for epidermolysis bullosa. Time to Wound Closure is as an acceptable efficacy endpoint for wound-related diseases, per FDA guidance. 1. Jay Barth, MD, Chief Medical Officer of Amic
5/19/17 - AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Other Events
AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Other Events Item 8.01. Other Events. On May19, 2017, Amicus Therapeutics,Inc. (the Company) issued a press release announcing the planned analysis of primary endpoints in its Phase 3 Epidermolysis Bullosa Study. A copy of this press release is attached hereto as Exhibit99.1. Item 9.01. Financial
AngioSoma is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease. Six Months Ended March 31, 2017. We recognized general and administrative expense of $356,702 for the six months ended...
5/19/17 - Atossa Genetics Completes Enrollment for Trial
Atossa Genetics announced it completed enrollment for a Phase 1 study of Endoxifen. Endoxifen is an active metabolite of the FDA- approved drug tamoxifen, which is used to treat breast cancer and for breast cancer prevention in high risk patients. The post Atossa Genetics Completes Enrollment for Trial appeared first on Investing News Network.
5/19/17 - Atossa Genetics Completes Enrollment in Topical Arm of Endoxifen Phase 1 Study
Atossa Genetics, Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it completed enrollment in the topical arm of its Phase 1 dose escalation study of Atossa's proprietary Endoxifen. The study is being conducted on behalf of Atossa by C
5/19/17 - Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol
Avenue Therapeutics, Inc., a Fortress Biotech Company, today announced that Notice of Allowance has now been received from the U.S. Patent and Trademark Office for a new patent application, entitled " Intravenous Administration of Tramadol. The patent application describes and claims a dosing regimen of intravenous 50 mg tramadol that provides
5/19/17 - Bayer receives FDA priority review for copanlisib to treat follicular lymphoma [Syrian Arab News Agency]
German drug manufacturer Bayer has received priority review designation for the new drug application for copanlisib from the US Food and Drug Administration. Bayer Pharmaceuticals America region head Carsten Brunn said: With this milestone, we are one step closer to making copanlisib available in the US to the community of doctors and patients faci
5/19/17 - Biogen Buys Remedy Pharma` Late-Stage Drug CIRARA [Syrian Arab News Agency]
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving treatments to people affected by central nervous system diseases and injuries, announced that Biogen completed an asset purchase of its Phase 3 candidate, CIRARA. The U.S. Food and Drug Administration recently granted CIRARA Orphan drug designation for..
5/19/17 - CDC Finalizes Vaccine Recommendation for Adults Traveling to Areas with Cholera
The Centers for Disease Control and Prevention's recommendation for the use of a cholera vaccine in adults traveling to areas with cholera is now final. The final recommendation was published today in CDC' s Morbidity and Mortality Weekly Report. It is approved for use in adults 18 through 64 years old and is the only FDA- approved cholera vaccine
5/19/17 - CDMO Kemwell Supplies Biologics Drug Substance for Phase 1 U.S. Clinical Trials [Tehran Times (Iran)]
Kemwell provided a fully integrated solution including technology transfer, process optimization, scale-up, manufacturing of toxicology materials and cGMP manufacturing of drug substance clinical materials. Kemwell aims to establish itself as a leading player in the one-stop-shop biopharmaceutical contract manufacturing space.
5/19/17 - Company Spotlight: GlycoMimetics
NEW YORK CITY- Shares of GlycoMimetics Inc. have exploded higher by more than 170% in the last 5 trading days in sharp contrast to the iShares NASDAQ Biotechnology Index, which is down 1.22% during the same period. GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GMI-1271 is designated as a Breakthr
5/19/17 - DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced its financial results for the quarter ending March 31, 2017, the third quarter of the Company s 2017 fiscal year. The Company also announced a collaboration with PRA Health Sciences as the contract r
5/19/17 - DelMar taps PRA Health Sciences to run pivotal brain cancer trial [Algeria Press Service]
It has already nabbed an orphan drug designation in Europe for gliomas, and it has also received orphan designations from the FDA for glioma, medulloblastoma and ovarian cancer. Following guidance from the FDA, the Vancouver, Canada- based biopharma companywith the help of MD Anderson Cancer Centerstarted a phase 2 trial in January to test the drug
5/19/17 - DGAP-News: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers (english)
MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers ^ DGAP-News: MorphoSys AG/ Key word: Study results MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers 19.05. 2017/ 07:30 The issuer is solely responsible for the content of this announcement.
5/19/17 - Electronic Clinical Outcome Assessment (eCOA) Solutions Market - By Delivery Mode (Web-Hosted, Licensed Enterprise, Cloud-Based) & End Use (Hospitals, CROs, Academic Institutes, Biotech & Pharma) - Research and Markets
Research and Markets has announced the addition of the "Electronic Clinical Outcome Assessment Solutions Market, 2014-2025" report to their offering. The global electronic clinical outcome assessment solutions market is expected to reach USD 2.16 billion by 2025. The complexity in healthcare information management is anticipated to fuel the demand
5/19/17 - Epizyme Announces Path Toward Tazemetostat Registration in Epithelioid Sarcoma and Reports New Clinical Data to be Presented at ASCO [Tehran Times (Iran)]
-Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced positive interim data on its first-in-class EZH2 inhibitor, tazemetostat, from the epithelioid sarcoma cohort of its ongoing Phase 2 study in adult patients with molecularly defined solid tumors. In addition, the Company announced that it
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement